Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

医学 癌症研究 抗体-药物偶联物 免疫组织化学 抗体 癌症 连接蛋白 胰腺癌 病理 单克隆抗体 内科学 细胞 免疫学 生物 细胞粘附 遗传学
作者
Pia M. Challita-Eid,Daulet Satpayev,Peng Yang,Zili An,Karen J.M. Morrison,Yuriy Shostak,Arthur B. Raitano,Rossana Nadell,Wendy J. Liu,Dawn Ratay Lortie,Linnette Capo,Alla Verlinsky,Monica Leavitt,Faisal Malik,Héctor Aviña,Claudia I. Guevara,Nick Dinh,Sher Karki,Banmeet S. Anand,DANIEL SANTIAGO PEREIRA
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:76 (10): 3003-3013 被引量:761
标识
DOI:10.1158/0008-5472.can-15-1313
摘要

The identification of optimal target antigens on tumor cells is central to the advancement of new antibody-based cancer therapies. We performed suppression subtractive hybridization and identified nectin-4 (PVRL4), a type I transmembrane protein and member of a family of related immunoglobulin-like adhesion molecules, as a potential target in epithelial cancers. We conducted immunohistochemical analysis of 2,394 patient specimens from bladder, breast, lung, pancreatic, ovarian, head/neck, and esophageal tumors and found that 69% of all specimens stained positive for nectin-4. Moderate to strong staining was especially observed in 60% of bladder and 53% of breast tumor specimens, whereas the expression of nectin-4 in normal tissue was more limited. We generated a novel antibody-drug conjugate (ADC) enfortumab vedotin comprising the human anti-nectin-4 antibody conjugated to the highly potent microtubule-disrupting agent MMAE. Hybridoma (AGS-22M6E) and CHO (ASG-22CE) versions of enfortumab vedotin (also known as ASG-22ME) ADC were able to bind to cell surface-expressed nectin-4 with high affinity and induced cell death in vitro in a dose-dependent manner. Treatment of mouse xenograft models of human breast, bladder, pancreatic, and lung cancers with enfortumab vedotin significantly inhibited the growth of all four tumor types and resulted in tumor regression of breast and bladder xenografts. Overall, these findings validate nectin-4 as an attractive therapeutic target in multiple solid tumors and support further clinical development, investigation, and application of nectin-4-targeting ADCs. Cancer Res; 76(10); 3003-13. ©2016 AACR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liu的应助被LLMs采纳,获得10
刚刚
李爱国的应助被季喃采纳,获得10
刚刚
刚刚
1秒前
隐形曼青的应助被Arthur采纳,获得10
1秒前
整齐的傲云完成签到,获得积分10
1秒前
Arslanker完成签到,获得积分10
2秒前
YB完成签到,获得积分10
2秒前
2秒前
俞静怡发布了新的文献求助30
3秒前
ZJ完成签到,获得积分10
3秒前
3秒前
ccc完成签到 ,获得积分10
3秒前
super chan完成签到,获得积分10
3秒前
gsh发布了新的文献求助10
4秒前
xhy完成签到,获得积分10
4秒前
5秒前
5秒前
jt完成签到,获得积分10
5秒前
顾矜的应助被Zcccjy采纳,获得10
5秒前
小新AA发布了新的文献求助10
6秒前
研友_VZG7GZ的应助被Zcccjy采纳,获得10
6秒前
传奇3的应助被Zcccjy采纳,获得10
6秒前
winstar发布了新的文献求助10
6秒前
共享精神的应助被Liugz采纳,获得10
6秒前
尊敬的寄松的应助被Zcccjy采纳,获得10
6秒前
丘比特的应助被Zcccjy采纳,获得30
6秒前
烟花的应助被Zcccjy采纳,获得10
6秒前
Hello的应助被xueee采纳,获得10
6秒前
Vanff发布了新的文献求助10
7秒前
秃头的彬彬完成签到,获得积分10
7秒前
xjh的应助被Zcccjy采纳,获得10
7秒前
可爱的函函的应助被和谐竺采纳,获得10
7秒前
欢乐轮回发布了新的文献求助10
7秒前
7秒前
7秒前
科研通AI6.2的应助被ruby采纳,获得10
8秒前
激情的健柏完成签到 ,获得积分10
8秒前
Emotional完成签到 ,获得积分10
8秒前
刘俊豪发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153442
求助须知:如何正确求助?哪些是违规求助? 9550127
关于积分的说明 21696715
捐赠科研通 7741908
什么是DOI,文献DOI怎么找? 3425483
关于科研通互助平台的介绍 2550608
邀请新用户注册赠送积分活动 2469152